| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 08/10/2023 | Aceragen, Inc. | IDRA | Sale | Common Stock | 51 | $0.51 | $26 | By Trust | 08/10/2023 |
| 06/08/2023 | Merus N.V. | MRUS | Grant | Share option (right to buy) | 14.4k | $23.29 | $335.7k | | 06/08/2023 |
| 06/02/2023 | Aclaris Therapeutics, Inc. | ACRS | Exercise | Restricted Stock Units | 4.5k | $0.00 | $0 | | 06/01/2023 |
| 06/01/2023 | Aclaris Therapeutics, Inc. | ACRS | Grant | Stock Option (Right to Buy) | 15.8k | $8.70 | $137k | | 06/01/2023 |
| 06/01/2023 | Aclaris Therapeutics, Inc. | ACRS | Grant | Restricted Stock Units | 4.7k | $0.00 | $0 | | 06/01/2023 |
| 05/25/2023 | Passage BIO, Inc. | PASG | Grant | Director Stock Option (Right to Buy) | 24k | $1.00 | $24k | | 05/25/2023 |
| 06/23/2022 | Aceragen, Inc. | IDRA | Grant | | 26k | $0.46 | $11.9k | | 06/23/2022 |
| 06/03/2022 | Aclaris Therapeutics, Inc. | ACRS | Exercise | Restricted Stock Units | 3.4k | $0.00 | $0 | | 06/02/2022 |
| 06/02/2022 | Aclaris Therapeutics, Inc. | ACRS | Grant | Restricted Stock Units | 4.5k | $0.00 | $0 | | 06/02/2022 |
| 06/02/2022 | Aclaris Therapeutics, Inc. | ACRS | Grant | Stock Option (Right to Buy) | 15.8k | $14.48 | $228.1k | | 06/02/2022 |
| 05/31/2022 | Passage BIO, Inc. | PASG | Grant | Stock Option (Right to Buy) | 40k | $1.80 | $72k | | 05/31/2022 |
| 05/31/2022 | Merus N.V. | MRUS | Grant | Share option (right to buy) | 16.6k | $18.56 | $308.2k | | 05/31/2022 |
| 05/26/2022 | Passage BIO, Inc. | PASG | Grant | Director Stock Option (Right to Buy) | 24k | $1.76 | $42.2k | | 05/26/2022 |
| 06/08/2021 | Aceragen, Inc. | IDRA | Grant | | 26k | $1.31 | $34.1k | | 06/08/2021 |
| 06/03/2021 | Aclaris Therapeutics, Inc. | ACRS | Grant | Stock Option (Right to Buy) | 12.2k | $21.90 | $268.3k | | 06/03/2021 |
| 06/03/2021 | Aclaris Therapeutics, Inc. | ACRS | Grant | Restricted Stock Units | 3.4k | $0.00 | $0 | | 06/03/2021 |
| 05/28/2021 | Merus N.V. | MRUS | Grant | Share option (right to buy) | 12.2k | $21.15 | $258.9k | | 05/28/2021 |
| 05/28/2021 | Merus N.V. | MRUS | Grant | Share option (right to buy) | 12.2k | $21.15 | $258.9k | | 05/28/2021 |
| 05/27/2021 | Passage BIO, Inc. | PASG | Grant | Director Stock Option (Right to Buy) | 4.5k | $13.83 | $62.8k | | 05/27/2021 |
| 02/18/2021 | Passage BIO, Inc. | PASG | Grant | Stock Option (right to buy) | 33.8k | $21.46 | $726.1k | | 02/18/2021 |
| 06/08/2020 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 4.6k | $12.05 | $55k | | 06/05/2020 |
| 06/05/2020 | Akebia Therapeutics, Inc. | AKBA | Grant | Stock Option (Right to buy) | 20.1k | $11.96 | $240.4k | | 06/05/2020 |
| 06/05/2020 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 13.7k | $0.00 | $0 | | 06/05/2020 |
| 06/04/2020 | Aclaris Therapeutics, Inc. | ACRS | Grant | Option Grant (right to buy) | 16.5k | $1.41 | $23.3k | | 06/04/2020 |
| 05/13/2020 | TREVENA INC | TRVN | Grant | Stock Option (Right to Buy) | 64.1k | $1.05 | $67.3k | | 05/13/2020 |
| 05/12/2020 | Aceragen, Inc. | IDRA | Grant | | 11.5k | $1.97 | $22.7k | | 05/12/2020 |
| 03/02/2020 | Aclaris Therapeutics, Inc. | ACRS | Exercise | Restricted stock units | 4.4k | $0.00 | $0 | | 03/02/2020 |
| 03/02/2020 | Aclaris Therapeutics, Inc. | ACRS | Grant | Restricted stock units | 4.4k | $0.00 | $0 | | 03/02/2020 |
| 07/02/2019 | Aclaris Therapeutics, Inc. | ACRS | Grant | Stock option (right to buy) | 16k | $2.34 | $37.4k | | 07/02/2019 |
| 06/06/2019 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 13.7k | $0.00 | $0 | | 06/06/2019 |
| 06/06/2019 | Akebia Therapeutics, Inc. | AKBA | Grant | Stock Option (Right to buy) | 20.1k | $4.23 | $85k | | 06/06/2019 |
| 06/04/2019 | Aceragen, Inc. | IDRA | Grant | | 11.5k | $2.57 | $29.6k | | 06/04/2019 |
| 05/16/2019 | TREVENA INC | TRVN | Grant | Stock Option (Right to Buy) | 30k | $1.34 | $40.2k | | 05/16/2019 |
| 02/01/2019 | TREVENA INC | TRVN | Purchase | Common Stock | 50k | $1.02 | $51k | | 02/01/2019 |
| 06/20/2018 | Aceragen, Inc. | IDRA | Grant | | 50k | $1.53 | $76.5k | | 06/20/2018 |
|